Flagship Biosciences Presents PD-L1 Scoring Method at SITC 2017 that could Eliminate Reliance on Complex Multiplex IHC Assays

Novel cTA™-based morphometric biomarker interpretation approach quantifies immune cells in tumor tissues and has potential to revolutionize PD-L1 diagnostics landscape National Harbor, MD – November 11th 2017 – Flagship Biosciences, Inc., the leading developer of quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics to drive clinical decisions for industry partners, presented data today […]

Read More

Flagship Biosciences, Inc. Receives Prestigious Best Research Award for Poster on PD-L1 Harmonization at Pathology Visions 2017 Conference

Westminster, CO, Oct. 4, 2017 – Flagship Biosciences was honored to receive the award for Best Poster in the Research Category at the Pathology Visions 2017 annual conference in San Diego, CA for their poster on Evaluating Image Analysis Approaches Toward “Harmonization” of PD-L1 Assays. The poster describes how Flagships’ proprietary Computational Tissue Analysis (cTA™) […]

Read More

Flagship Biosciences Provides Analytically Validated Tools to Assist in the Analysis of Summit’s PhaseOut DMD Clinical Trial

CLSI compliant analytically validated cTA™ tools for 2 duplex IHC assays presented at the 22nd annual meeting of the World Muscle Society St. Malo, France, October, 5th, 2017 – Flagship Biosciences, Inc., the leading developer of quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics to drive clinical decisions for industry partners, presented today […]

Read More

Flagship Biosciences to Present at the Next Generation Dx Summit

Get the Whole Picture with both Content and Context August 9, 2017 – Westminster, CO – Flagship Biosciences, the leading partner for drug developers investigating tissue-based biomarkers, announced today that they will be a significant contributor to the strategic and scientific dialogue at the Next Generation Dx Summit in Washington DC, August 14th – 16th. […]

Read More

Flagship Biosciences’ support of Summit Therapeutics highlighted at the 2017 Needham Healthcare Conference

Glyn Edwards, CEO of Summit Therapeutics, plc and speaker at the Needham Healthcare Conference, highlighted the work that Flagship Biosciences is doing to support automated analyses of muscle biopsies in Summit’s on-going Phase 2 clinical trial for DMD. These analyses have the potential to support proof of concept for Summit’s utrophin modulator, ezutromid. In response […]

Read More

Flagship Biosciences to Demonstrate Benefits of Computational Tissue Analysis for Clinical Pipeline Decisions at ASCO

The benefits of increased confidence and clarity for clinical trial decisions will be presented by Flagship’s team at the Annual Meeting of the American Society of Clinical Oncology, June 2nd – 6th, at McCormick Place, Chicago, IL. Visit Flagship at @ASCO booth #25115 and learn more about Flagship’s plans for the meeting at BioSpace.

Read More

Is PD-L1 Harmonization on the Horizon?

Dr. Joseph Krueger, Flagship Bioscience’s Chief Scientific Officer, was recently interviewed by BioCentury about cTA™ harmonization or the potential to use one predictive assay to calibrate the output from multiple assays. Dr. Krueger provided insight about how the cTA™ platform could not only calibrate results across multiple assays, but can optimize cutoff points for patient […]

Read More

Flagship Biosciences to present quantitative tissue-based data on five clinical trial and immuno-oncology topics at AACR

Flagship Biosciences’ Computational Tissue Analysis (cTA™) and decision support platform featured in five scientific poster presentations at the American Association for Cancer Research Annual Meeting, April 1-5, 2017, in Washington, D.C. Visit Flagship at @AACR booth #1553 and learn more about the posters at BioSpace.

Read More

Flagship Biosciences to exhibit at SITC Annual Meeting 2016 with two immune cell analysis posters

Booth #127 November 11-13, National Harbor, MD National Harbor, MD – Nov. 2 2016 – Flagship Biosciences, the leader in tissue image analysis, announced today that they will be presenting new data at the Annual Meeting of the Society for Immunotherapy of Cancer being held November 11-13, with exhibits from Nov. 11-12. Flagship’s scientists will […]

Read More

Flagship’s computational Tissue Analysis (cTA™) tools support Summit’s DMD drug development

Flagship develops cTA™ tools and duplex IHC assays for muscle biopsy evaluation in support of disease-modifying therapies for Duchenne muscular dystrophy Granada, Spain – October 18th, 2016 – Data and findings featuring Flagship’s computational Tissue Analysis (cTA™) in the development of biomarker analysis tools to support Duchenne muscular dystrophy (DMD) drug development were presented by […]

Read More